Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab in Children With Relapsed/Refractory Solid Tumors
NCT00831844Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2009
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of cixutumumab in hepatoblastoma, synovial sarcoma (SS), rhabdomyosarcoma (RMS), adrenocortical carcinoma (ACC), Ewing sarcoma, sponsored by National Cancer Institute. Started Jan 2009; status: completed.
02
Drugs
cixutumumab
03
Conditions
hepatoblastomasynovial sarcoma (SS)rhabdomyosarcoma (RMS)adrenocortical carcinoma (ACC)Ewing sarcoma
Beyond the preview
Go deeper on NCT00831844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00831844.